These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18034595)

  • 1. Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Cosimo Prantera.
    Prantera C
    Drugs; 2007; 67(17):2643-4. PubMed ID: 18034595
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Ake Nilsson.
    Nilsson A
    Drugs; 2007; 67(17):2643-4. PubMed ID: 18034596
    [No Abstract]   [Full Text] [Related]  

  • 3. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis.
    McCormack PL; Robinson DM; Perry CM
    Drugs; 2007; 67(17):2635-42. PubMed ID: 18034594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.
    Russo L; Schneider G; Gardiner MH; Lanes S; Streck P; Rosen S
    Eur J Clin Pharmacol; 2014 Jun; 70(6):709-17. PubMed ID: 24609467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.
    Yang LP; McCormack PL
    Drugs; 2011 Jan; 71(2):221-35. PubMed ID: 21275447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
    Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
    Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations.
    D'Amico F; Lusetti F; Peyrin-Biroulet L; Danese S
    Dig Liver Dis; 2024 Sep; 56(9):1425-1432. PubMed ID: 38705783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
    Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
    Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
    Riley SA
    Gut; 1998 Jun; 42(6):761-3. PubMed ID: 9691909
    [No Abstract]   [Full Text] [Related]  

  • 15. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J; Yuan Y
    Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J; Yuan Y
    Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: impact of MMX mesalazine on health-related quality of life in ulcerative colitis.
    Marsh AM; Lobo AJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):402. PubMed ID: 22803649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.